All In Biotech

Drug Trial Radar · NCT03100318

Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout

Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 for Hyperuricemia With or Without Gout to Evaluate the Safety and Noninferiority of FYU-981 (Phase III Study)

Last checked: Nov 19, 2026Latest source record: Sep 26, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 201 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

201

Actual

Start

Apr 1, 2017

Primary completion

Apr 25, 2018

Study completion Aug 31, 2018

Sponsor

Lead sponsor
Fuji Yakuhin Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Mochida Pharmaceutical Company, Ltd.
First posted
Apr 4, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

FYU-981 or Benzbromarone are administrated to hyperuricemia patients with or without gout for 14 weeks to compare the efficacy and safety of these drugs by the method of multicenter, randomized, double-blind, ascending dose regimen.

Conditions

  • Hyperuricemia With or Without Gout

Interventions

  • FYU-981Drug

    Oral daily dosing for 14 weeks

  • BenzbromaroneDrug

    Oral daily dosing for 14 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent reduction from baseline in serum urate level at the final visitTime frame: 14 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tokyo

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.